• Explore /
  • Poster
  • / EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.

Abstract Poster

Authors

Charu Aggarwal

Charu Aggarwal

Perelman Center for Advanced Medicine, Philadelphia, PA

Charu Aggarwal , Christopher G. Azzoli , Alexander I. Spira , Benjamin J. Solomon , Xiuning Le , Christian Rolfo , David Planchard , Enriqueta Felip , Yi-Long Wu , Myung-Ju Ahn , Tanguy Y. Seiwert , Koichi Goto , Analía Azaro , Delphine Lissa , Oday Hamid , Lara McGrath , Rhiannon Maudsley , FERNANDA I ARNALDEZ , Italia Grenga , Erminia Massarelli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05647122

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3156)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3156

Abstract #

TPS3156

Poster Bd #

352b

Abstract Disclosures

Similar Posters

First Author: Omar Saavedra Santa Gadea

First Author: Jonathan N. Priantti

First Author: Ye Guo

First Author: Jonathan W. Goldman